Results from an exploratory analysis of characterization of long-term survivors (LTS), defined in the study as people who survived for longer than 18 months following randomization, in the IMpower133 trial will be presented in a mini-oral session. The study previously showed that atezolizumab in combination with chemotherapy helped people with extensive-stage small cell lung cancer (ES-SCLC) live significantly longer compared with chemotherapy alone. SCLC is distinguished from other lung cancer subtypes due to its aggressive nature, rapid growth and early development of metastatic disease.
In addition, four-year survival data from the phase II POPLAR and phase III OAK studies, investigating atezolizumab vs docetaxel (chemotherapy) in patients with advanced pre-treated non-small cell lung cancer (NSCLC) will be presented.
